Arcutis Biotherapeutics Inc Ordinary Shares ARQT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $27.74
- Day Range
- $26.09–27.25
- 52-Week Range
- $13.70–31.75
- Bid/Ask
- $26.93 / $27.01
- Shares Outstanding
- 125.08M
- Market Cap
- $3.36B
- Volume/Avg
- 455,956 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 126.85
- Price/Sales
- 8.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 354
- Website
- https://www.arcutis.com
Valuation
|
Metric
|
ARQT
|
|---|---|
Price/Earnings (Normalized) | 126.85 |
Price/Book Value | 18.79 |
Price/Sales | 8.78 |
Price/Cash Flow | 86.19 |
Price/Earnings
ARQT
Financial Strength
|
Metric
|
ARQT
|
|---|---|
Quick Ratio | 2.26 |
Current Ratio | 2.68 |
Interest Coverage | 0.07 |
Quick Ratio
ARQT
Profitability
|
Metric
|
ARQT
|
|---|---|
Return on Assets (Normalized) | 7.71% |
Return on Equity (Normalized) | 18.46% |
Return on Invested Capital (Normalized) | 11.59% |
Return on Assets
ARQT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|XSy?yx | LOCK|HJC@f | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|JcXtL? | LOCK|zN^m | $70B | |||
| argenx SE ADR
ARGX
| LOCK|CnN&PZ | LOCK|xkY | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|L$@jQz | LOCK|tt<k | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|h###H? | LOCK|zQK | $36B | |||
| Moderna Inc
MRNA
| LOCK|S%v?^d | LOCK|<#J | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|m?&RC!x@ | LOCK|#c&$w | $25B | |||
| Incyte Corp
INCY
| LOCK|<mmCwy | LOCK|tKN | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!r?qS<% | LOCK|M@ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%yxR>@> | LOCK|W#S | $17B |
United States